The Association between DRD3 Ser9Gly Polymorphism and Depression Severity in Parkinson’s Disease

Table 2

Demographic data of participants.

Items	PD		HC
	Ser/Ser ()	Ser/Gly or Gly/Gly ()	Ser/Ser ()	Ser/Gly or Gly/Gly ()
Gender (male/female)	22/13	19/7	10/10	19/8	0.372^a
Age (years)	68 (44–81)	65.5 (49–88)	64.5 (52–72)	63 (55–72)	0.119^b
Education (years)	11 (6–20)	12 (5–17)	12 (5–22)	12 (5–16)	0.845^b
Disease duration (years)	4 (0.25–13)	3.125 (0.5–20)	NA	NA	0.930^c
H&Y stage	2 (1–3)	2 (1–3)	NA	NA	0.424^c
LEDD (mg/day)	375 (0–1025)	400 (0–837.5)	NA	NA	0.965^c
UPDRS-III	22 (8–48)	22 (5–40)	NA	NA	0.815^c
MMSE	29 (26–30)	29 (24–30)	NA	NA	0.477^c
FAB	16 (10–18)	16 (10–18)	NA	NA	0.489^c
Tinetti Balance	14 (4–16)	14 (3–16)	NA	NA	0.555^c
Tinetti Gait	9 (2–12)	8.5 (4–12)	NA	NA	0.959^c
FSS	28 (9–55)	26 (8–57)	NA	NA	0.569^c
HAMD-17	2 (0–16)	4.5 (1–21)	NA	NA	0.012
HAMA	7 (1–18)	9 (2–24)	NA	NA	0.270^c
Apathy	14 (2–36)	17.5 (1–32)	NA	NA	0.310^c
ESS	5 (0–14)	4.5 (0–11)	NA	NA	0.282^c
Anhedonia score^&	0 (0–2)	1 (0–4)	NA	NA	0.004

Abbreviations: PD, Parkinson’s disease; HC, healthy control; H&Y stage, Hoehn and Yahr stage; LEDD, levodopa-equivalent daily dose; UPDRS, Unified Parkinson’s Disease Rating Scale; MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Battery; FSS, Fatigue Severity Scale; HAMD, Hamilton Depression Scale; HAMA, Hamilton Anxiety Scale; ESS, Epworth Sleepiness Scale; NA, not applicable. Values except gender were expressed as median (range). ^aChi-square tests. ^bTwo-way analysis of variance (ANOVA). ^cMann–Whitney U tests. ^&Anhedonia score was measured by a single anhedonia item in the HAMD scale. was considered significant.